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https://doi.org/10.1016/j.stemcr.2019.03.004SUMMARYEmerging evidence suggests that Parkinson’s disease (PD), besides being an age-associated disorder, might also have a neurodevelopment
component. Disruption of mitochondrial homeostasis has been highlighted as a crucial cofactor in its etiology. Here, we show that PD
patient-specific humanneuroepithelial stem cells (NESCs), carrying the LRRK2-G2019Smutation, recapitulate keymitochondrial defects
previously described only in differentiated dopaminergic neurons. By combining high-content imaging approaches, 3D image analysis,
and functional mitochondrial readouts we show that LRRK2-G2019S mutation causes aberrations in mitochondrial morphology and
functionality compared with isogenic controls. LRRK2-G2019S NESCs display an increased number of mitochondria compared with
isogenic control lines. However, these mitochondria are more fragmented and exhibit decreased membrane potential. Functional alter-
ations in LRRK2-G2019S cultures are also accompanied by a reducedmitophagic clearance via lysosomes. These findings support the hy-
pothesis that preceding mitochondrial developmental defects contribute to the manifestation of the PD pathology later in life.INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder
affecting 1% of the population more than 60 years old
(Tysnes and Storstein, 2017). The key histopathological hall-
mark of the disease is the degenerationofdopaminergicneu-
rons in the substantia nigra of themidbrain. The cause of the
disease is still unknown. However, a complex interplay be-
tween genetic and environmental factors might contribute
to its pathogenesis (for review see Burbulla and Kruger,
2011). The dysregulation of mitochondrial function has
beenhighlighted as a crucial player, because complex I activ-
ity was shown to be reduced in PD patients (Schapira et al.,
1990). More recently, various PD-specific cellular models re-
vealed impaired mitochondrial morphology and transport,
increased release of reactive oxygen species (ROS), and
reduced mitochondrial motility compared with controls
(Hsieh et al., 2016; Smith et al., 2016; Trimmer et al.,
2000). Dopaminergic neurons in the substantia nigra have
higher energy demands compared with other types of neu-
rons because of the production of the neurotransmitter
dopamine, and the particularly long, highly branched, and
unmyelinatedaxons (Pissadaki andBolam,2013). Therefore,
they are particularly susceptible to mitochondrial dysfunc-878 Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019 j ª 2019 The Auth
This is an open access article under the CC BY-NC-ND license (http://creativtions compared with other types of neurons (for review
see Haddad and Nakamura, 2015). These mitochondrial
dysfunctions might be caused by genetic alterations and/
or environmental impacts. Several genetic variants are
associatedwith the risk of developingPD (Klein andWesten-
berger, 2012). Interestingly, mutations in the gene encod-
ing leucine-rich repeat serine/threonine-protein kinase 2
(LRRK2) have been associated with both familial and
sporadic PD (Funayama et al., 2002; Lesage et al., 2007; Oze-
lius et al., 2006). The autosomal-dominant genomic muta-
tion (c.6055 G>A), which results in a LRRK2-p.G2019S
(G2019S) substitution, is themost prevalent genetic risk fac-
tor for PD (Funayama et al., 2002; Paisan-Ruiz et al., 2004).
LRRK2 cellular functions have not yet been fully defined.
However, LRRK2 is thought to contribute to autophagy
and mitochondrial regulation (Roosen and Cookson,
2016),microtubule dynamics (Krumova et al., 2015), micro-
RNA activity regulation (Gonzalez-Cano et al., 2018), and
vesicular trafficking (Cookson,2016). It is located in thecyto-
plasm and associated with membranes (Vitte et al., 2010;
West et al., 2005). Recently, LRRK2-G2019S has proven to
be associated with autophagosomal-endosomal-lysosomal
pathways related to mitochondrial health and biogenesis
(Roosen and Cookson, 2016; Wallings et al., 2015).or(s).
ecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. LRRK2-G2019S Alters Mitochondrial Gene Expression
Profile
(A and B) Cartoon and tables illustrating the cell lines used and the
grouping applied.
(C) Histograms showing cumulative gene expression distributions
for mitochondrial-specific genes in NESCs and during dopami-
nergic differentiation (10, 14, and 42 days). For each cell, a score
called cumulative gene expression was defined as the sum of the
gene expression for all the genes associated to mitochondria
(details are provided in the Experimental Procedures). These are
the genes present in the targeted list of genes specific for
mitochondria (Table S1), generated based on the available liter-
ature (Calvo et al., 2016). Cells having a higher cumulative gene
expression are cells for which the expression of mitochondrial-
specific genes is high. For each condition (PD2/WT, PD2/G2019S
N = 1, n = 3) and for each day, 250 cells were considered, for a
total of 2,000 cells. The statistical significance of the difference
in population average between the two genotypes is indicated in
each panel and was obtained by means of a z test including
Bonferroni correction for multiple hypothesis testing. The fre-
quency reported on the vertical axes represents the number of
cells in each bin of the histogram, normalized in a way that each
distribution has a surface equal to 1. N indicates the number of
experimental repetitions, n indicates the number of technical
replicates per cell line.Neural progenitor stem cells have been highlighted as
a meaningful model for mitochondria-related disease phe-
notyping (Lorenz et al., 2017). Here, we use PD patient-spe-
cific induced pluripotent stem cell (iPSC)-derived
neuroepithelial stem cells (NESCs) to assess mitochondrial
features. NESCs are an easily accessible and highly homoge-
neous model representing early brain development. We
observed that mitochondria in NESCs carrying the
LRRK2-G2019S mutation were more fragmented and
more prone to release ROS compared with isogenic con-
trols. Also, the functionality of mitochondria was impaired
in patient-specific stem cells as shown by the decreased
membrane potential and respiratory capacity.RESULTS
In our study, we used 13 human iPSC-derived NESC lines
obtained from three patients carrying the LRRK2-G2019S
mutation and four age- and gender-matched healthy indi-
viduals. Four isogenic NESC lines (two in which the muta-
tion was introduced and two in which the mutation was
corrected) were also generated (Figures 1A and 1B). For
patient 1 two different clones were used (PD.1 and
PD1.1). The use of isogenic controls enabled us to distin-
guish between LRRK2-G2019S-dependent and -indepen-
dent phenotypes. The derivation and characterization
of NESCs from iPSCs have been described previously (Rein-
hardt et al., 2013).
Throughout the article, unless otherwise stated, we indi-
cate whether the donor was healthy (H) or affected by the
pathology (PD). LRRK2 genotype is annotated according to
the absence (WT) or presence of the LRRK2-G2019S muta-
tion (G2019S). Cells from a healthy individual are
indicated as H/WT, and after the introduction of LRRK2-
G2019S as H/G2019S (isogenic control). Cells from a PD
patient with the LRRK2-G2019S mutation are annotated
as PD/G2019S, and after genetic correction of LRRK2-
G2019S as PD/WT. The use of these groupings allowed us
to distinguish between effects due to LRRK2-G2019Smuta-
tion and effects that depend on the individual’s genetic
background. We first compared all NESC lines only(D) Venn diagram representing the differentially expressed genes
(DEGs) specific for mitochondria. Each ensemble contains the DEGs
at a given time point. The total number of mitochondrial DEGs for
the corresponding time point is indicated in brackets. The numbers
indicate how many DEGs fall into the area of the Venn diagram.
Where graphically possible, we report the names of the genes,
instead of their number. The names of the genes common to all four
time points are reported in bold in the center of the diagram. By
definition, the sum of the numbers of genes appearing into each of
the four ensembles is equal to the total number of DEGs for that day,
reported in brackets.
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according to their LRRK2 genotype (H + PD/G2019S versus
H + PD/WT). Then, we compared cells from LRRK2-G2019S
patients with cells from age- and gender-matched controls
(PD/G2019S versus H/WT); third, we compared samples
from PD patients with their isogenic controls (PD/
G2019S versus PD/WT). Finally, we investigated the impact
of introducing the LRRK2-G2019S mutation in a healthy
genetic background (H/WT versus H/G2019S).
LRRK2-G2019S Induces Mitochondrial Gene
Expression Alterations
Mitochondrial dysfunctions have been previously associ-
ated to LRRK2-G2019S in iPSC-derived neurons (Burbulla
and Kruger, 2011). To determine whether LRRK2-G2019S
mutation affected mitochondrial-related genes also at the
NESC level or only after dopaminergic differentiation,
we performed droplet-based (Drop-seq) single-cell RNA
sequencing (RNA-seq). Here, we focused on the cells from
an early-onset patient (PD2/G2019S) and the correspond-
ing isogenic control cells (PD2/WT). We first generated a
targeted list specific for mitochondrial genes (Table S1)
based on an inventory of human genes encoding mito-
chondrial-localized proteins (www.broadinstitute.org/
pubs/MitoCarta) (Calvo et al., 2016). We profiled 2,000
quality-controlled cells and, after in silico pre-processing
of the data, we calculated cumulative gene expression
scores for themitochondrial-based defined gene list (details
are provided in the Experimental Procedures section). The
analysis of the cumulative gene expression distribution
(Figure 1C) showed significant gene expression differences
between the genotypes at the different neuronal differenti-
ation time points assessed (10, 14, and 42 days). Interest-
ingly, a significant difference in mitochondria-related
genes was already observed in the NESCs carrying the
LRRK2-G2019S compared with the LRRK2-WT, before in-
duction of differentiation. Hence, we decided to focus our
analysis on NESCs to better characterize the mitochondrial
defects appearing already in this cell type. To gain more in-
sights into the dynamics of themitochondrial gene expres-
sion levels, for each day we computed the differentially
expressed genes (DEGs) between LRRK2-WT and LRRK2-
G2019S. We observed that, among the total genes (approx-
imately 17,000) in common between all the time points in
our dataset, the numbers of DEGs at days 0, 10, 14, and 42
were, respectively, 619, 531, 318, and 1,637 (Table S2). This
corresponds to approximately 4%, 3%, 2%, and 10% of the
total genes. Since our focus is mitochondria, we considered
the DEGs that were present in Table S1. Among these mito-
chondria-related genes, the number, of those differentially
expressed at days 0, 10, 14, and 42were, respectively 73, 38,
15, and 241. These are equivalent to respectively 6%, 3%,
1%, and 21% of the total number of mitochondrial genes
in our list. The change of this percentage across the880 Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019different days reflects the trend observed in the overall per-
centage of DEGs across the whole genome, thus overall it is
not only a feature of the mitochondria-related genes. On
the other hand, the most remarkable difference is in the
percentage of DEGs at day 42, which is 10% across the
whole genome, but 21% (i.e., more than twice) across
the list of mitochondrial genes. This indicates that the
expression of mitochondria-related genes is dramatically
different between LRRK2-WT and LRRK2-G2019S at day
42. We further investigated whether the genes that are
differentially expressed between LRRK2-WT and LRRK2-
G2019S are different or similar at different time points.
We then considered the list of DEGs among the mitochon-
dria-specific genes at each day, and intersect every possible
combination of lists, and count the number of DEGs in the
intersection (Figure 1D). Themajority of themitochondria-
related genes are differentially expressed only at one time
point. However, four genes are differentially expressed at
every time point: ATP5G2, RPS15A, CHCHD2, and
RPL35A. An additional 12 genes are differentially expressed
at 3 different time points. Notably, PARK7 (or DJ1) is differ-
entially expressed between LRRK2-WT and LRRK2-G2019S
at days 0, 10, and 42. Interestingly, of the 16 genes that are
DEGs at 3 or 4 time points, there are 3 that encode compo-
nents of ATP synthases (ATP5G2, ATP5I, and ATP5E).
Perhaps less surprisingly, among these 16 DEGs at 3 or
4 days, there are 5 genes that correspond to ribosomal pro-
teins, namely RPS15A, RPS18, RPL10A, RPL34, and
RPL35A, and a sixth one, RPS14, is a DEG at day 10 and
14. We also notice that, among the DEGs that are common
between days 10 and 42, we find GAPDH, which codes for
an enzyme that catalyzes the sixth step of glycolysis, and
has been found to be implicated in several neurodegenera-
tive diseases including PD.
LRRK2-G2019S Induces Mitochondrial Fragmentation
in NESCs
Under normal physiological conditions, cells maintain a
well-balanced mitochondrial fission/fusion ratio, and any
divergence from this stable homeostasis indicates problems
in mitochondria functionality (Youle and van der Bliek,
2012). These alterations are usually indicated by frag-
mented or elongated mitochondrial morphology (Wu
et al., 2011). We analyzed mitochondrial morphometrics
via immunocytochemistry using an antibody against the
translocase of outer mitochondrial membrane 20 protein
(TOM20) (Narendra et al., 2008) and established an
automated high-content screening (HCS) 2D imaging
single-cell analysis approach to unbiasedly quantify mito-
chondrial features.We analyzed themitochondrial staining
with respect to the number of mitochondria per cell (Fig-
ures 2A and S1A). NESCs carrying LRRK2-G2019S from PD
patients exhibited significantly more mitochondria per
Figure 2. LRRK2-G2019S Induces Mitochondrial Fragmentation in NESCs
(A–C) Automated single-cell analysis of mitochondrial morphology in pooled groups. The number of cells is indicated in each bar (N = 3,
n = 3). The following parameters were assessed: (A) number of mitochondria per cell; (B) mean mitochondrial sphericity; (C) Feret ratio.
(D–J) Unbiased/blinded manual 3D single-cell analysis of the mitochondrial features of selected cell lines (H1/WT, H1/G2019S, PD1/WT,
and PD1/G2019S). Each dot plotted represents data from a single analyzed cell (n cells per group indicated in I; N = 3, n = 3). Statistical
significance was determined using Student’s t test. (D) Representative z stack maximum intensity projections of single cells and corre-
sponding post-processing showing segmented mitochondria in different colors. The x-axis indicates the size of the mitochondria in mm.
The following parameters were assessed: (E) number of mitochondria per cell; (F) mean mitochondrial sphericity; (G) mean Feret ratio of
mitochondria; (H) surface area of mitochondria (SAm) (mm2); (I) mitochondrial volume (Vm) per cell (mm3); (J) percentage of small-
volume mitochondria (0.02–2 mm2).
(K) Total ROS levels normalized to H1, N = 5–6, n = 3, Mann-Whitney test was performed within isogenic groups.
(L) Mitochondrial ROS levels normalized to H1, N = 4, n = 1 Mann-Whitney test was performed within isogenic groups.
(M) Mitochondrial content measurements normalized to H1, N = 4, n = 2, Mann-Whitney test was performed within isogenic groups. For all
panels, the data are presented as the mean (only 1 median) ± SEM. N indicates the number of experimental repetitions, n indicates the
number of technical replicates per cell line.cell than their isogenic controls and H individuals. Inser-
tion of the mutation in the H background did not exert
the same effect. Next, we quantified sphericity and elonga-
tion of individual mitochondria (Nikolaisen et al., 2014)
and compared the mean values of these parameters per
cell (Figures 2B and S1B). In agreement with the previousfinding, the analysis revealed significantly higher mito-
chondrial sphericity in LRRK2-G2019S cultures compared
with controls. We next used the Feret ratio (Igathinathane
et al., 2008), which takes into account the shortest and
longest extensions of mitochondria as a measure of their
elongation (Figures 2C and S1C). Feret ratio analysisStem Cell Reports j Vol. 12 j 878–889 j May 14, 2019 881
showed significantly smaller ratios of Feret maxima and
minima in cells from patients compared with H, indicating
that these cells contained less elongatedmitochondria than
cells from healthy individuals. Correction of the mutation
in PD patients and insertion of the mutation in H did not
significantly affect this parameter.
To verify these findings and explore additional morpho-
logical details, we next conducted a detailed 3D analysis of
mitochondrial morphology in NESCs. We selected two
isogenic pairs derived from a healthy line (H1) and a
LRRK2-G2019S carrier PD patient (PD1.1) (Figure 2D).
The 3D analysis revealed an increased number of mito-
chondria (Figure 2E) in LRRK2-G2019S NESCs. When
calculated per cell, and under mitochondrial subpopula-
tion analyses, mitochondria from LRRK2-G2019S NESCs
displayed greater sphericity (Figures 2F, S1D, and S1E), a
reduced Feret ratio (Figures 2G, S1F, and S1G), and an
increased volume fraction (percentage) of small mitochon-
dria (Figure 2H) compared with isogenic controls. The
total mitochondrial surface area (Figure 2I) and volume
(Figures 2J, S1H, and S1I) increased in LRRK2-G2019S
NESCs compared with the LRRK2-WT NESCs, suggesting
that LRRK2-G2019S NESCs had an increased mitochon-
drial biomass. The increase did not reach statistical signifi-
cance in PD patient cells when compared with their
isogenic controls. Based on the results of the two different
mitochondrial morphology analyses, we concluded that
increased levels of mitochondrial fragmentation were pre-
sent in LRRK2-G2019S NESCs. This suggests that the
LRRK2-G2019S mutation interferes with mitochondrial
dynamics, suggesting reduced mitochondrial quality.
LRRK2-G2019S Causes Increased Total and
Mitochondrial ROS Levels
As LRRK2-G2019S induced aberrant mitochondrial mor-
phologies, we evaluated the possible negative effects in
terms of oxidative stress. Mitochondria passively release
the main fraction of total cellular ROS (Turrens, 2003),
and increased ROS release is a direct indicator of mitochon-
drial dysfunction (Lambeth et al., 2007). Therefore, we
performed a general analysis of total ROS levels using a
luminescence-based system. We detected significantly
increased ROS levels in LRRK2-G2019S NESCs compared
with controls (Figures 2K and S1J). Correction of the
LRRK2-G2019S mutation in the patient lines was insuffi-
cient to significantly rescue the total ROS levels. On the
other hand, the insertion of the LRRK2-G2019S mutation
in the healthy background induced increased ROS levels
compared with the isogenic controls. We then assessed
mitochondria-specific superoxide levels using a MitoSOX
probe using flow cytometry (Figures 2L, S1K, and S1L).
The resulting data revealed significantly elevated mito-
chondrial ROS (mROS) levels in cells expressing LRRK2-882 Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019G2019S. Correction of the LRRK2-G2019S mutation
rescued mROS levels, but healthy control cells with the in-
serted mutation showed no elevation in mROS (Figure 2L).
We next measured the mitochondrial content of NESCs
using flow cytometry with the MitoTracker probe and
observed an increased amount in NESCs carrying the
LRRK2-G2019S mutation (Figures 2M, S1M, and S1N).
This increase did not reach statistical significance in the
comparisons H versus P and P/WT versus P/G2019S.
Overall, these results indicate that LRRK2-G2019S-ex-
pressing NESCs exhibited a higher degree of mitochondrial
fragmentation and morphological alterations than mito-
chondria in LRRK2-WT NESCs. When comparing H/WT
with H/G2019S, it was apparent that the amplitude of the
phenotypes was smaller than when comparing H/WT
with P/G2019S. This suggests that LRRK2-G2019S muta-
tion plays a deleterious effect on mitochondria, which
can be exacerbated by a permissive genetic background.
LRRK2-G2019S Alters Mitochondrial Functionality
To address whether LRRK2-G2019S also functionally
altered mitochondria, we analyzed mitochondrial respira-
tion and mitochondrial membrane potential (MMP). The
oxygen consumption rate (OCR) was measured with the
Seahorse Extracellular Flux Analyzer (Figures 3A–3D and
S2A–S2E). LRRK2-G2019S NESCs showed a significantly
decreased basal respiration compared with LRRK2-WT (Fig-
ures 3A and S2A).We injected oligomycin to determine the
proportion of ATP-linked OCR, followed by FCCP, an un-
coupling compound, used to induce maximal respiration.
LRRK2-G2019S NESCs showed a significantly reduced
maximal respiration capacity compared with LRRK2-WT.
The same differences were observed when comparing
H/WT and PD/G2019S (Figures 3B and S2B), PD/WT and
PD/G2019S patients (Figures 3C and S2C), and H/WT and
H/G2019S lines (Figures 3D and S2D). Proton leakage was
unchanged between the tested conditions. We next
analyzed MMP, another parameter indicating mitochon-
drial quality (Brand and Nicholls, 2011). Using TMRM
dye, we detected significantly lower MMP in LRRK2-
G2019S-expressing NESCs compared with LRRK2-WT (Fig-
ures 3E and S2F).
We also assessed the viability of the NESCs using propi-
dium iodide (Pi) staining via flow cytometry. The Pi+ quan-
tification revealed increased cell death in LRRK2-G2019S
NESC cultures compared with LRRK2-WT (Figures 3F–H).
In a previous study, increased cell death was observed in
NSC LRRK2-G2019S cultures after the addition of a protea-
some inhibitor (Liu et al., 2012). It was previously reported
that neural stem cells are competent to differentiate into
neurons, astrocytes, and oligodendrocytes (Conti et al.,
2005), but they do not efficiently differentiate in midbrain
dopaminergic neurons (Reinhardt et al., 2013). This
Figure 3. LRRK2-G2019S Induces Loss of Respiratory Capacity
and Cell Death
(A–D) Mitochondrial total respiratory capacity measurements ob-
tained using Seahorse, N = 3, n = 8 of the following cell groupings
(A) H + PD/WT and H + PD/G2019S, (B) H/WT and PD/G2019S, (C)
PD/WT and PD/G2019S, (D) H/WT and H/G2019S. Maximal respi-
ration, proton leakage, basal respiration, ATP production, and non-
mitochondrial respiration are represented with OCR graphs shown
on the left and with spider plots on the right. Data in the spider plotdifferent behavior stresses the relevance of NESCs for the
study of PD. Comparing PD1/WT with PD1/G2019S, the
increase did not reach statistical significance.
Together, these findings suggest that mitochondria are
functionally altered in LRRK2-G2019S NESCs and this is
associated with increased cell death.
LRRK2-G2019S Triggers Aberrant Mitochondrial
Quality Control
Mitochondrial functionality and turnover are ultimately
linked. The effective clearance of dysfunctional mitochon-
dria is strongly dependent on the autophagosomal-lyso-
somal pathway (ALP). The mitochondrial phenotypes we
observed in LRRK2-G2019S-expressing NESCs are poten-
tially the result of ineffective mitochondrial clearance,
which might be the result of insufficient ALP function
(Youle and van der Bliek, 2012). Macromitophagy is ALP
mediated (Figure 4A). Thus, we speculated that ALP in
LRRK2-G2019S NESCs could be affected, potentially result-
ing in insufficient mitochondrial clearance. Accordingly,
we performedHCS-based lysosome quantification to detect
differences in the final and rate-limiting step of ALP.
After unbiased identification of all lysosomal-associated
membrane protein 2-positive (LAMP2+) areas in single cells
(Figure 4B), we quantified the LAMP2+ puncta representing
the total pool of lysosomes, including potential non-acidi-
fied pre-lysosomes. We quantified lysosome number and
total lysosomal area (Figures 4C, S3A, and S3B). Based on
these features, we calculated the mean size of all lysosomes
(Figures 4D and S2C). The approach revealed a reduced
number of lysosomes, reduced total lysosomal area, and
reduced mean lysosomal size in LRRK2-G2019S-expressing
NESCs compared with LRRK2-WT. In most comparisons,
these lysosomal phenotypes were directly associated with
LRRK2-G2019S mutation. However, the results obtained
with H/G2019S isogenic controls indicated that LRRK2-
G2019S itself is not sufficient to affect the total lysosomal
area per NESC feature. We next addressed the potentialwere calculated based on the grouped data points of the oxygen
consumption rates. Significant differences between the groups
were tested using a two-way ANOVA, as indicated in the graphs.
(E) Mitochondrial membrane potential (MMP) quantification. The
data were normalized to MitoTracker 488 live staining and H1 data.
Statistical significance was tested using Student’s t-test.
(F–H), (F) Flow cytometry scatter plots showing the gating strategy
for the Pi quantification of the NESC population. (G) Representative
histograms showing the Pi+ cell fraction in the H1/WT and PD1/
G2019S NESCs. (H) Bar graphs showing the resulting Pi+ cell
quantification in all the applied groupings, , N = 3–4, n = 1. In all
panels, the data are presented as the mean ± SEM. N indicates the
number of experimental repetitions, n indicates the number of
technical replicates per cell line.
Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019 883
Figure 4. LRRK2-G2019S Impairs Mito-
chondrial Quality Control
(A) Illustration depicting the mito-
chondrial clearance pathway via lysosomes
(adapted from Fullgrabe et al., 2014), high-
lighting staining methods and chloroquine
perturbation.
(B) Representative photomicrographs of
LAMP2 ICC-based lysosome quantification;
HCS-based feature detection is indicated.
(C–E) HCS-based quantification of lysosomal
morphological features per cell, grouped
comparisons (N = 3, n = 3); the number of
single cells analyzed is indicated in each bar.
Statistical significance was analyzed using
Mann-Whitney test. The following parame-
ters were assessed: (C) number of lysosomes
and lysosomal area per cell; (D) mean lyso-
some size per cell; (E) mitophagy level esti-
mation using quantification of lysosomal
(LAMP2) and mitochondrial (TOM20) stain-
ing co-localization events. Representative
TOM20 and LAMP2 photomicrographs are
shown with co-localization in white (the
co-localization events may be in another z
plane). The number of cells analyzed is
indicated in the bars.
(F–I) Western blot-based autophagy activity
and stress activation analysis in NESCs
(N = 3, n = 3). Statistical significance was
determined using two-way ANOVA and Tukey
multiple comparisons test (*comparison
with untreated PD2.GC cells; #comparison
with untreated PD2.G2019S cells; and
xcomparison with PD2.GC cells—same
condition). (F) Quantification of LC3B I/II
protein levels under basal conditions
and during blocking of autophagosomal-
lysosomal fusion (CLQ, chloroquine) in
combination with activation of autophagy using Earle’s balanced salt solution-based starvation. (G) Calculation of net flux autophagic
activity. (H) Relative basal SQSTM1 protein levels. (I) Upstream autophagy activation signal analysis using Beclin-1. Scale bars, 20 mm. For
all panels, the data are presented as the mean ± SEM. N indicates the number of experimental repetitions, n indicates the number of
technical replicates per cell line.mitophagy events by quantifying the co-localization of
LAMP2 puncta with the mitochondrial TOM20 area in sin-
gle NESCs (Figures 4E and S2D).We detected a significantly
reduced number of co-localization in LRRK2-G2019S-
expressing NESCs compared with controls, indicating
reduced macro-mitophagic clearance via lysosomes.
To investigate the potential dysregulation of the ALP up-
streamof the lysosome, we performed a protein-based anal-
ysis of autophagosomal capacity using cells of one patient
and its isogenic control (PD2/WTand PD2/G2019S). Using
western blotting analysis (Figures 4F–4I), we measured the
protein levels of the autophagosomal membrane-bound884 Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019form of LC3B (LC3B-II) (Figure 4F), sequestesome 1
(SQSTM1, also known as p62) (Figures 4H and S3E), and Be-
clin-1 (Figure 4I), widely used markers for monitoring the
autophagic process, in the absence or in the presence of
chloroquine, an inhibitor of ALP degradation.
We observed significantly elevated basal autophagic flux
activity in LRRK2-G2019S-expressing NESCs compared
with LRRK2-WT (Figure 4G). Consistently, the autophagy
substrate SQSTM1 levels were elevated in these cells (Figures
4H and S3G). Next, we tested the cellular autophagy
response to Earle’s balanced salt solution-induced starva-
tion. Despite the observed elevated basal autophagic level
in the patient cells, these levels were not sustained during
starvation (Figure 4F). Although starvation resulted in
continuously elevated LC3BII levels in controls, the pres-
ence ofCLQ, the LC3BII levels inLRRK2-G2019S-expressing
NESCs were markedly decreased compared with controls.
Strikingly, parallel quantification of Beclin-1 (Figure 4I),
which acts upstream of autophagy signaling and activation
(Kang et al., 2011), indicated a strong activation signal, as re-
flected by elevatedBeclin-1 levels (3 and6h) and in thepres-
ence of CLQ 100 mM. However, the Beclin-1 signal did not
result in autophagosome formation because of the lack of
LC3BII abundance under the same conditions (Figure 4I).
These results show that LRRK2-G2019S negatively affects
autophagy upstream of the observed lysosomal limitations.
Collectively, the ALP analysis of NESCs revealed
decreased ALP functionality in LRRK2-G2019S-expressing
NESCs compared with isogenic controls.DISCUSSION
In this study, we observed that mitochondria in NESC cells
carrying the LRRK2-G2019S mutation were more frag-
mented and were more prone to release ROS compared
with isogenic controls. Beside morphology, also the func-
tionality of mitochondria was impaired in the presence of
LRRK2-G2019S, as shown by the decreased membrane po-
tential and respiratory capacity.
Evidence fromhumanneuronshaspreviously shown that
LRRK2 influences mitochondrial function (Cooper et al.,
2012; Sanders et al., 2014) and dynamics (Wang et al.,
2012). An increase of fragmented mitochondria has been
observed in iPSC-derived dopaminergic neurons along
with impaired clearance of unhealthy mitochondria, and
alteration in mitochondria respiration and bioenergetics,
as reviewed in Sison et al. (2018). However, no information
was previously available regarding the status of the mito-
chondria at the stem cell level in the context of LRRK2.
Here, we showed that already before neuronal differentia-
tion at the level of NESCs, mitochondrial phenotypes are
detectable, suggesting that this is a relevant model to study
PD mitochondrial alterations. Moreover, mitochondria
were recently shown to be of crucial importance in neural
stem cells (Lorenz et al., 2017; Sanders et al., 2014), high-
lighting their key role in cell fate decisions during develop-
ment (Beckervordersandforth et al., 2017; Khacho et al.,
2016). Mitochondria are critically involved in numerous
cellular processes that rely on energy, such as cell growth,
maintenance, proliferation, activity, and neurogenesis
(Beckervordersandforth et al., 2017). Based on these find-
ings, it is tempting to speculate that thedescribedmitochon-
drial alterations in NESCs are important contributors to the
PD-specific dynamics of dopaminergic differentiation.Neurogenic niches are characterized by particularly
elevated metabolic activity, which associates with high
ROS levels (Walton et al., 2012). Beside their detrimental ef-
fect on cell viability, ROS play a role in the regulation of
neural cell fate (Khacho et al., 2016; Orford and Scadden,
2008; Sarsour et al., 2009). Consequently, the observed
elevated ROS levels might contribute to the increased cell
death observed in LRRK2-G2019S NESCs. LRRK2 mutation
can alter the interaction with the antioxidant protein per-
oxiredoxin 3, reducing the ability to scavenge ROS (Angeles
et al., 2011). It has been shown that mitochondria-targeted
antioxidants effectively sequester ROS and protect against
mitochondrial damage (Oyewole and Birch-Machin,
2015). NESCs are stable and highly proliferative cultures,
which permit quick evaluation of functional and morpho-
logical mitochondrial features. The present model and the
here-described assays can leverage pharmacological screen-
ings that aim to ameliorate bioenergetics defects and
reduce mitochondrial ROS in the context of PD.
Control of mitochondrial homeostasis is of major impor-
tance in cellular homeostasis (Dias et al., 2013). Insufficient
clearance of dysfunctional mitochondria is associated with
accumulation of damaged mitochondria and high ROS
levels, ultimately resulting in reduced cell viability. Clear-
ance of malfunctioning mitochondria largely occurs
through lysosomal-mediated mitophagy. Lysosomal dys-
functionality has been associated to PD in several studies
(Chang et al., 2017; Roosen andCookson, 2016). The status
of mitochondrial biogenesis can be directly linked to the
functionality of mitochondrial quality control mecha-
nisms (Tronstad et al., 2014). Lysosomal phenotypes in
PD context have mostly been described in terminally
differentiated neurons (Migdalska-Richards et al., 2017).
Here, we also found LRRK2-G2019S-associated alterations
in the ALP in NESCs, indicating that ALP dysregulation
can already occur at a developmental stage.
In summary, the data presented in this study highlight
disease-specific phenotypes of patient-derived NESCs car-
rying the LRRK2-G2019S mutation. The detection of these
phenotypes in a developmentally early neural stem cell
model supports the hypothesis that PDmight have a devel-
opmental component.EXPERIMENTAL PROCEDURES
The work with human iPSCs was approved by the local ethical
committee (Ethic Review Panel of the University of Luxembourg,
PDiPS project and CNER No 201305/04).
Single-Cell RNA-Seq Using Drop-Seq
Microfluidics Fabrication
Microfluidics devices were fabricated using a previously published
design (Macosko et al., 2015). Soft lithography was performedStem Cell Reports j Vol. 12 j 878–889 j May 14, 2019 885
using previously published protocols using SU-8 2050 photoresist
(MicroChem) on a 400 silicon substrate (Macosko et al., 2015;Mazu-
tis et al., 2013). Drop-seq chips were fabricated using silicon-based
polymerization chemistry. In brief, a polydimethylsiloxane
(PDMS) base and a crosslinker (Dow Corning), were combined at
a 10:1 ratio, mixed, and degassed, before pouring the mix onto
the Drop-seqmaster template. PDMSwas cured on themaster tem-
plate, at 80C for 2 h. After the incubation and cooling, the PDMS
stamps were cut and the inlet/outlet ports were punched with
1.25-mm biopsy punchers (World Precision Instruments). The
PDMS monolith was plasma-bonded to a clean microscopic glass
slide using Harrick plasma cleaner. The flow channels of the
Drop-seq chip were then subject to hydrophobicity treatment.Single-Cell Suspension and RNA-Seq
The key steps of the protocol used here align with the original
Drop-seq work (Macosko et al., 2015) with minor changes as
described below. After the enzymatic digestion of the cells using
Accutase at 37C (10–20min) single cells were pelleted by centrifu-
gation at 300 rcf for 5 min. Cell clumps and debris were excluded
from the suspension using a 40-mm nylon cell strainer (BD). The
single-cell suspension was diluted with 1% BSA in 13 PBS to
achieve a cell density of 150 cells/mL. Diluted cells were placed
on ice until loaded onto the pre-fabricated Drop-seq chip. Specially
synthesized barcoded beads (ChemGenes) were co-encapsulated
with cells inside the droplets, having optimized lysis reagents
adapted from Macosko et al. (2015). This procedure allows
capturing the cellular mRNA by barcoded oligo (dT) handles on
the surface of the specialized beads. The microfluidic chip gener-
ates monodispersed droplets of 1 nL volume. The bead concen-
tration used for optimal single bead encapsulation within the
droplet was 200 beads/mL, and beads were prepared in Drop-seq
lysis buffer (Macosko et al., 2015).
Oneml of the cell and the bead suspensionwas loaded into 3-mL
syringes (BD). A micro-stirrer was used (V&P Scientific) to keep the
beads in stable suspension. The QX200 carrier oil (Bio-Rad) was
used as a continuous phase in the droplet generation. Oil was
loaded into a 20-mL syringe (BD). For droplet generation, 3.6
and 13 mL/h were used for the dispersed and continuous phases,
respectively, using KD Scientific Legato syringe pumps. This gener-
ated droplets with a diameter of 115 mm (1 nL volume). The
droplet suspension was collected in a 50-mL Falcon tube. Then,
the droplet consistency and stability were documented by bright-
field microscopy to check on multiple bead occupancy.
The subsequent droplet breakage, reverse transcription, and the
exonuclease treatment were carried out in accordance with the
original Drop-seq work (Macosko et al., 2015). The buffer for
the reverse transcription contained: 13 Maxima RT buffer, 4%
Ficoll PM 400 (Sigma), 1 mM dNTPs (Thermo Scientific), 1 U/mL
RNase Inhibitor (Lucigen), 2.5 mM Template Switch Oligo, and
10 U/mL Maxima H Minus RT (Thermo Scientific).
Following Exo I treatment, the bead counts were estimated using
an INCYTO C-Chip disposable hemacytometer. Then, aliquots of
10,000 beads were prepared in 0.2-mL Eppendorf PCR tubes. PCR
mix was dispensed in a volume of 50 mL using 13 Hifi HotStart
ReadyMix (Kapa Biosystems) and 0.8 mM Template-Switch-PCR
primer. The thermocycling program for the PCR amplification886 Stem Cell Reports j Vol. 12 j 878–889 j May 14, 2019was adapted from the previous work, except for the final PCR cy-
cles: 95C for 3 min; four cycles of: 98C for 20 s, 65C for 45 s,
72C for 3 min; 10 cycles of: 98C for 20 s, 67C for 20 s, 72C
for 3 min; followed by a final extension step of 72C for 5 min. Af-
ter PCR amplification, libraries were purified with 0.63 Agencourt
AMPureXP beads (BeckmanCoulter), in accordancewith theman-
ufacturer’s protocol. Finally, the purified libraries were eluted in
20 mL of molecular-grade water. Before the sequencing library
preparation, the quality and the concentration of the libraries
was assessed using Bioanalyzer High Sensitivity Chip (Agilent
Technologies).
3D Blinded Unbiased Mitochondrial Morphology
Analysis
3D image processing and analysis based on LSM confocal z stacks
were performed using Image-Pro Plus software (version 7.0) with
SharpStack Total deconvolution and 3D Constructor modules
(Media Cybernetics, Washington, USA). Analysis of mitochon-
drial shape properties was conducted by adapting previously
described protocols (Nikolaisen et al., 2014). The mitochondrial
channel of the confocal z stack was extracted, background-cor-
rected (fixed level), and spatially calibrated and 3D blind decon-
volution (10 iterations) was performed. Flat 2D projections
(maximum intensity composite) of the mitochondrial z stacks
were employed for manual segmentation of single cells, but we
also compared with the nuclear and cytoplasmic channels
(F-actin) as guidance in this step. By drawing the cellular outline,
a binary black and white image was created, and this was subse-
quently used as a mask for making a z stack with only one (or
two) cell(s). The processed single-cell z stacks were loaded into
the 3D Constructor module using no sub-sampling, and an iso-
surface (surface level = 900) was created without further filtering
or simplification. Mitochondrial shape-parameters were then ob-
tained and analyzed. Objects larger than 0.02 mm3 were quanti-
fied as mitochondrial objects.
The quantitative image analysis was done with blinded samples.
Pooled single-cell data obtained from three replicated experiments
are presented. The inter-experimental variation was evaluated and
found insignificant (not shown). Statistical analysis of two groups
was performedusing t test. Only cells thatwere possible to segment
into single cells or doublets (only a few cases) were included in this
analysis. For doublets, the mean value was used for statistical
analysis. Cells that were clearly apoptotic (condensed nucleus,
fragmented cell body) were excluded. Samples in this analysis
(n = number of cells analyzed): PD1.G2019S n = 69, PD1.GC:
n = 90, H1.G2019S: n = 72, H1: n = 66.
Quantification and Statistical Analysis
Statistical analysis was performed as follows: unpaired or paired
(isogenic controls) Student’s t test when the sample size was small
and data normally distributed. For HCS imaging data that was not
normally distributed we applied Mann-Whitney test. Two-way
ANOVA followed by Bonferroni test was applied when indicated.
All data are presented as mean ± SEM. Significance levels were set
at *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
For plotting, GraphPad Prism was used. For single-cell RNA-seq
data, the statistical significance of the differences in cumulative
gene expressions (Figure 1C) was assessed using a z test, with Bon-
ferroni correction to account for multiple testing. More details
on the different statistical analyses of single-cell RNA-seq data
are explained in the section titled ‘‘Analysis of Mitochondrial
genes expression at the single cell level’’ of the Supplemental
Information.
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